HOLX Quote, Financials, Valuation and Earnings

Becton, Dickinson & Co. has a net margin of 17.85% compared to Hologic, Inc.'s net margin of 8.37%. Hologic, Inc.'s return on equity of 11.59% beat Becton, Dickinson & Co.'s return on equity of 6.6%.

Hologic, Inc. has a consensus price target of $76.50, signalling upside risk potential of 2.69%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $204.83 which suggests that it could grow by 4.68%. Given that Becton, Dickinson & Co. has higher upside potential than Hologic, Inc., analysts believe Becton, Dickinson & Co. is more attractive than Hologic, Inc..

Hologic, Inc. has a beta of 0.703, which suggesting that the stock is 29.745% less volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.828%.

Hologic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Becton, Dickinson & Co. offers a yield of 2.13% to investors and pays a quarterly dividend of $1.05 per share. Hologic, Inc. pays -- of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hologic, Inc. quarterly revenues are $1B, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. Hologic, Inc.'s net income of $187.3M is lower than Becton, Dickinson & Co.'s net income of $493M. Notably, Hologic, Inc.'s price-to-earnings ratio is 30.00x while Becton, Dickinson & Co.'s PE ratio is 33.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic, Inc. is 4.13x versus 2.59x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis, Inc. has a net margin of 17.85% compared to Hologic, Inc.'s net margin of 21.11%. Hologic, Inc.'s return on equity of 11.59% beat Nuwellis, Inc.'s return on equity of -1004.06%.

Hologic, Inc. has a consensus price target of $76.50, signalling upside risk potential of 2.69%. On the other hand Nuwellis, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 22436.61%. Given that Nuwellis, Inc. has higher upside potential than Hologic, Inc., analysts believe Nuwellis, Inc. is more attractive than Hologic, Inc..

Hologic, Inc. has a beta of 0.703, which suggesting that the stock is 29.745% less volatile than S&P 500. In comparison Nuwellis, Inc. has a beta of -0.165, suggesting its less volatile than the S&P 500 by 116.484%.

Hologic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic, Inc. pays -- of its earnings as a dividend. Nuwellis, Inc. pays out -- of its earnings as a dividend.

Hologic, Inc. quarterly revenues are $1B, which are larger than Nuwellis, Inc. quarterly revenues of $2.2M. Hologic, Inc.'s net income of $187.3M is higher than Nuwellis, Inc.'s net income of $468K. Notably, Hologic, Inc.'s price-to-earnings ratio is 30.00x while Nuwellis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic, Inc. is 4.13x versus 0.55x for Nuwellis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 17.85% compared to Hologic, Inc.'s net margin of -862.39%. Hologic, Inc.'s return on equity of 11.59% beat VolitionRX Ltd.'s return on equity of --.

Hologic, Inc. has a consensus price target of $76.50, signalling upside risk potential of 2.69%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 763.76%. Given that VolitionRX Ltd. has higher upside potential than Hologic, Inc., analysts believe VolitionRX Ltd. is more attractive than Hologic, Inc..

Hologic, Inc. has a beta of 0.703, which suggesting that the stock is 29.745% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Hologic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Hologic, Inc. quarterly revenues are $1B, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Hologic, Inc.'s net income of $187.3M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Hologic, Inc.'s price-to-earnings ratio is 30.00x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic, Inc. is 4.13x versus 17.45x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging Corp. has a net margin of 17.85% compared to Hologic, Inc.'s net margin of 5.33%. Hologic, Inc.'s return on equity of 11.59% beat Varex Imaging Corp.'s return on equity of -13.35%.

Hologic, Inc. has a consensus price target of $76.50, signalling upside risk potential of 2.69%. On the other hand Varex Imaging Corp. has an analysts' consensus of $17.20 which suggests that it could grow by 42.62%. Given that Varex Imaging Corp. has higher upside potential than Hologic, Inc., analysts believe Varex Imaging Corp. is more attractive than Hologic, Inc..

Hologic, Inc. has a beta of 0.703, which suggesting that the stock is 29.745% less volatile than S&P 500. In comparison Varex Imaging Corp. has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.269%.

Hologic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic, Inc. pays -- of its earnings as a dividend. Varex Imaging Corp. pays out -- of its earnings as a dividend.

Hologic, Inc. quarterly revenues are $1B, which are larger than Varex Imaging Corp. quarterly revenues of $228.9M. Hologic, Inc.'s net income of $187.3M is higher than Varex Imaging Corp.'s net income of $12.2M. Notably, Hologic, Inc.'s price-to-earnings ratio is 30.00x while Varex Imaging Corp.'s PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic, Inc. is 4.13x versus 0.63x for Varex Imaging Corp.. Usually stocks with elevated PS ratios are considered overvalued.